Zifi Turbo 600 Tablet contains Linezolid 600 mg, an oxazolidinone class antibiotic effective against a broad spectrum of Gram-positive bacterial infections. It is primarily indicated for the treatment of serious infections caused by susceptible strains of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), and penicillin-resistant Streptococcus pneumoniae. Linezolid exerts its antibacterial effect by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the functional 70S initiation complex essential for bacterial translation. Zifi Turbo 600 is commonly prescribed for complicated skin and soft tissue infections, nosocomial pneumonia, community-acquired pneumonia, and infections caused by multidrug-resistant organisms. The recommended dosage and duration of therapy should be determined by the severity of infection and patient-specific factors. Caution is advised in patients with a history of myelosuppression, and regular monitoring of blood counts is recommended during prolonged therapy. Linezolid may interact with serotonergic agents, increasing the risk of serotonin syndrome. Adverse effects can include headache, diarrhea, nausea, and reversible myelosuppression. Zifi Turbo 600 should be used under strict medical supervision to ensure optimal therapeutic outcomes and minimize resistance development.